Pfizer will receive exclusive worldwide rights to commercialize TransTech's portfolio of compounds, while TransTech will receive upfront and milestone payments of $155 million with the potential for more. TransTech will also receive royalties on worldwide sales of products.
The compounds currently undergoing trials target the receptor for advanced glycation end products, which is associated with several diseases.
TransTech Pharma is a majority-owned affiliate of MacAndrews & Forbes Holdings.